Affinage

CCR8

C-C chemokine receptor type 8 · UniProt P51685

Length
355 aa
Mass
40.8 kDa
Annotated
2026-04-28
100 papers in source corpus 43 papers cited in narrative 43 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CCR8 is a Gαi-coupled CC chemokine receptor that directs immune cell trafficking, survival, and immunosuppressive function across diverse tissue contexts. Its primary endogenous ligands are CCL1, CCL8, and CCL18, which bind an N-terminal domain requiring tyrosine sulfation at Y14/Y15; ligand engagement activates pertussis toxin-sensitive Gαi signaling, the RAS/MAPK/ERK anti-apoptotic pathway, STAT3-dependent enhancement of Treg suppressive programs (FOXP3, CD39, IL-10, granzyme B), and β-arrestin-mediated receptor internalization (PMID:9211859, PMID:12645948, PMID:28533380, PMID:17023422, PMID:14736884). CCR8 is preferentially expressed on Th2 cells, FOXP3+ regulatory T cells, dendritic cell subsets, ILC2s, monocytes/macrophages, and thymocytes, where it mediates chemotaxis to sites of allergic inflammation, helminth defense, and tissue homeostasis; in the tumor microenvironment, CCR8 expression is driven by TCR/NF-κB and TNFR2/NF-κB signaling and marks clonally expanded tumor-antigen-reactive Tregs whose selective depletion by ADCC-competent anti-CCR8 antibodies restores antitumor immunity and generates immunological memory without systemic autoimmunity (PMID:9670926, PMID:11560999, PMID:21217759, PMID:35140181, PMID:33757978, PMID:33589525, PMID:37935468). CCR8 also serves as an HIV-1 co-receptor on thymocytes and T cells and is exploited by viral chemokine mimics encoded by HHV-8 (vMIP-I agonist) and molluscum contagiosum virus (MC148 antagonist) (PMID:9417093, PMID:10419462, PMID:10620615).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1997 High

    Deorphanization of CCR8 established it as the specific Gαi-coupled receptor for CCL1 (I-309), resolving the ligand identity and G-protein coupling for this orphan seven-transmembrane receptor.

    Evidence Transfection of CCR8 into pre-B cells conferred CCL1-dependent calcium flux (EC50 ~2 nM) and chemotaxis blocked by pertussis toxin; radioligand binding measured Kd ~1.2 nM

    PMID:9207005 PMID:9211859

    Open questions at the time
    • No structural information on CCR8-CCL1 complex
    • Endogenous expression levels on primary cells not quantified
  2. 1998 High

    CCR8 was shown to be preferentially expressed on Th2-polarized T cells and to function as an HIV-1 co-receptor, defining its dual roles in adaptive immunity and viral pathogenesis.

    Evidence Northern blot/RT-PCR on polarized T cells; HIV-1 envelope-mediated fusion and infection assays in CCR8-transfected and primary thymocyte systems

    PMID:9417093 PMID:9480837 PMID:9670926 PMID:9820476

    Open questions at the time
    • In vivo relevance of CCR8 for HIV-1 tropism in patients not established
    • Mechanism of Th2-selective expression unknown
  3. 1999 High

    Viral chemokine mimics from HHV-8 (vMIP-I as agonist, vMIP-II as antagonist) and identification of MC148 as a highly selective CCR8 antagonist provided pharmacological tools and revealed that viruses exploit or block CCR8 to modulate host immunity.

    Evidence Comprehensive competitive binding across 65 chemokines, calcium mobilization, and chemotaxis assays in transfected cells and primary T cells

    PMID:10377196 PMID:10419462 PMID:10620615

    Open questions at the time
    • In vivo role of viral chemokine mimicry in HHV-8 or MCV pathogenesis not directly tested
    • Structural basis of vMIP-I agonism vs. MC148 antagonism unknown
  4. 2001 High

    Discovery that CCR8 marks CD4+CD25+ regulatory T cells and mediates their chemotaxis to CCL1 established the receptor as a key Treg surface marker and functional trafficking receptor.

    Evidence Flow cytometry and chemotaxis of sorted CD4+CD25+ vs CD25− T cells; functional alloproliferation assays

    PMID:11560999

    Open questions at the time
    • Whether CCR8 signaling has intrinsic effects on Treg suppressive function or only on migration was unresolved
    • CCR8 expression heterogeneity within Treg subsets not characterized
  5. 2003 High

    CCR8 was shown to activate the RAS/MAPK/ERK pathway to suppress apoptosis, establishing a survival signaling function beyond chemotaxis.

    Evidence Pertussis toxin, MEK inhibitor PD98059, dominant negative M-RAS, and MC148 antagonist all blocked CCL1/vMIP-I anti-apoptotic activity in thymic lymphoma cells

    PMID:12525579 PMID:12645948

    Open questions at the time
    • Physiological significance of CCR8 anti-apoptotic signaling in primary thymocyte selection not established
    • Downstream effectors of ERK in this context not identified
  6. 2004 High

    Structure-function analysis revealed that N-terminal tyrosine sulfation (Y14/Y15) is essential for CCL1 binding, establishing the molecular determinants of ligand recognition.

    Evidence Systematic site-directed mutagenesis (Tyr→Phe, Asn→Gln, Thr/Ser→Ala) with flow cytometry and calcium flux readouts; Y14F/Y15F double mutant was essentially inactive

    PMID:14736884

    Open questions at the time
    • No crystal or cryo-EM structure of sulfated CCR8
    • Whether tyrosine sulfation is regulated in vivo as a signaling switch is unknown
  7. 2006 High

    CCR8 internalization was shown to be β-arrestin 1/2-dependent and Gαi-independent, and Glu-286 in TM7 was identified as a critical residue for both receptor trafficking and small-molecule agonist binding, dissecting G-protein and arrestin signaling arms.

    Evidence β-arrestin overexpression/depletion, site-directed mutagenesis of Glu286, calcium flux, chemotaxis, and internalization assays

    PMID:17023422 PMID:17652183

    Open questions at the time
    • Biased signaling consequences for Treg biology not explored
    • Full agonist binding pocket model incomplete
  8. 2007 High

    In vivo studies using CCR8-deficient mice established that mast cell-derived CCL1 signals through CCR8 on CD4+ T cells to orchestrate allergic airway inflammation, and that CCR8 on macrophages drives peritoneal adhesion formation.

    Evidence CCR8−/− mice, mast cell-deficient mice, CCL1 neutralization, adenoviral CCL1 restoration, airway hyperresponsiveness; anti-CCL1/CCR8−/− adhesion models

    PMID:17404314 PMID:17641040

    Open questions at the time
    • Relative contribution of CCR8 on T cells vs. macrophages vs. DCs in airway inflammation unresolved
    • CCR4 was later shown to be more critical for Th2 lung entry
  9. 2011 High

    Identification of mouse CCL8 as a second endogenous CCR8 agonist driving Th2-mediated eosinophilic skin inflammation resolved a species-specific ligand difference and expanded the CCR8 ligand repertoire.

    Evidence Ccr8−/− and Ccl8−/− mice in chronic atopic dermatitis model; receptor binding and calcium flux confirmed CCL8 selectivity for CCR8 over CCR2

    PMID:21217759

    Open questions at the time
    • Whether human CCL8 acts similarly on human CCR8 not established
    • Role of CCL8-CCR8 beyond skin unclear
  10. 2013 High

    CCL18 was identified as a third endogenous human CCR8 ligand, broadening the receptor's physiological ligand repertoire.

    Evidence CCR8 transfection, competitive binding, calcium flux, internalization, cross-desensitization with CCL1, and CCR8−/− mouse Th2 cell migration

    PMID:23999500

    Open questions at the time
    • Relative contribution of CCL18 vs. CCL1 in different tissues not determined
    • CCL18 has no mouse ortholog, complicating in vivo validation
  11. 2017 High

    CCL1-CCR8 signaling was found to enhance Treg suppressive function via STAT3-dependent upregulation of FOXP3, CD39, IL-10, and granzyme B, and an autocrine CCL1 loop was discovered, shifting the view of CCR8 from a mere trafficking receptor to a direct modulator of Treg immunosuppressive programs.

    Evidence STAT3 inhibition, CCL1-Ig administration, CCR8−/− adoptive transfer in EAE model, flow cytometry for effector molecules

    PMID:28533380

    Open questions at the time
    • Whether STAT3 activation is direct or indirect not resolved
    • STAT3 vs. ERK pathway integration in Tregs unknown
  12. 2018 High

    CCR8 was shown to guide CD301b+ dendritic cell migration from the subcapsular sinus into lymph node parenchyma via Src-kinase signaling, establishing a non-T-cell function for CCR8 in initiating Th2 immunity.

    Evidence CCR8−/− mice, DC migration tracking by imaging and flow cytometry, Src kinase inhibition, CCL8 source identification in CD169+ macrophages

    PMID:30170811

    Open questions at the time
    • Whether CCR8 functions similarly in human lymph nodes not tested
    • Molecular details of CCR7-CCR8 synergy mechanism unresolved
  13. 2019 High

    CCR8 was identified as a therapeutic target on tumor-infiltrating Tregs: its expression is driven by TCR/NF-κB signaling, it marks tumor-specific Tregs, and ADCC-competent anti-CCR8 antibodies selectively deplete tumor Tregs to restore antitumor immunity without autoimmunity.

    Evidence scRNA-seq, NF-κB inhibition, nanobody-Fc ADCC assays, NK cell depletion, LLC-OVA and MC38 tumor models, anti-PD-1 synergy

    PMID:33589525

    Open questions at the time
    • CCR8 signaling was shown dispensable for Treg suppressive function in this study, contrasting STAT3/FOXP3 findings from 2017
    • Human clinical validation of anti-CCR8 therapy pending
  14. 2022 High

    CCR8+ tumor Tregs were demonstrated to be clonally expanded, tumor-antigen-reactive cells whose antibody-mediated depletion generates durable antitumor memory, and epigenetic regulation of CCR8 expression via histone H3K18 lactylation was discovered linking tumor metabolism to immunosuppression.

    Evidence scRNA-seq with TCR clonotype analysis; anti-CCR8 mAb depletion with tumor rechallenge; ChIP for H3K18 lactylation at CCR8 promoter with reporter assay and LDHA inhibitor

    PMID:35140181 PMID:37770937

    Open questions at the time
    • Whether lactylation-driven CCR8 upregulation is reversible therapeutically not tested
    • Relative contribution of NF-κB vs. lactylation vs. TNFR2 pathways in different tumor types unclear
  15. 2024 Medium

    TNFR2/NF-κB signaling was identified as an additional upstream pathway driving CCR8 expression in tumor Tregs, with FOXP3 directly binding the CCR8 promoter, and PD-1 blockade was found to paradoxically increase CCR8+ Treg infiltration.

    Evidence NF-κB/TNFR2 inhibition, FOXP3 ChIP, Tnfr2−/− tumor models, anti-PD-1 combination studies

    PMID:37935468

    Open questions at the time
    • Whether TNFR2 blockade combined with anti-CCR8 provides additive benefit is untested
    • Mechanism of PD-1 blockade-induced CCR8+ Treg expansion unknown
  16. 2025 High

    CCR8+ Tregs were shown to be essential for maternal-fetal immune tolerance, with decidual NK cell-derived CCL1 recruiting CCR8+ dTregs whose depletion caused fetal loss and whose adoptive transfer rescued it.

    Evidence scRNA-seq, TCR sequencing, CCR8+ dTreg depletion and adoptive transfer in abortion-prone mice, CCL1 source identification

    PMID:40249828

    Open questions at the time
    • Whether CCR8 signaling modulates dTreg suppressive programs or only trafficking is unclear
    • Human translational relevance for recurrent pregnancy loss not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: whether CCR8 signaling intrinsically enhances Treg suppressive function (conflicting evidence from STAT3 studies vs. dispensability findings), the structural basis of ligand selectivity and biased agonism, and whether anti-CCR8 antibody therapy achieves durable clinical responses in human cancers.
  • No high-resolution structure of CCR8 bound to any ligand
  • Conflicting reports on whether CCR8 signaling is required for Treg suppressive function vs. serving only as a depletion marker
  • No published human clinical efficacy data for anti-CCR8 therapy

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 5 GO:0098772 molecular function regulator activity 3
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-168256 Immune System 8 R-HSA-1643685 Disease 3
Partners
ARRB1ARRB2CCL1CCL18CCL8FOXP3GNAI1STAT3

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 CCR8 was identified as the specific receptor for the human CC chemokine I-309 (CCL1). Transfection of the CY6/TER1/CKR-L1 open reading frame into mouse pre-B cells conferred calcium flux and chemotaxis in response to I-309 (EC50 ~2 nM), while 20 other chemokines were inactive. Signaling was sensitive to pertussis toxin, indicating coupling to a Gi-type G protein. Receptor transfection into pre-B cells, calcium flux assay, chemotaxis assay, pertussis toxin inhibition, 125I-I-309 binding (Kd ~1.2 nM) The Journal of biological chemistry High 9211859
1997 CCR8 is constitutively expressed in monocytes and thymus, functions as a monocyte chemoattractant receptor for I-309, and inhibits apoptosis in thymic cell lines. Signaling is pertussis toxin-sensitive, confirming Gi coupling. Transfection, calcium flux, chemotaxis, pertussis toxin inhibition, northern blot for tissue expression The Journal of experimental medicine High 9207005
1998 CCR8 is preferentially expressed on polarized Th2 cells (both human and mouse) and not Th1 cells. The CCR8 ligands I-309 and TCA-3 act as potent chemoattractants specifically for Th2-polarized cells. Northern blot, RT-PCR, chemotaxis assay with polarized T cell subsets, mouse CCR8 cloning Journal of immunology (Baltimore, Md. : 1950) High 9670926
1998 CCR8 expression on Th2 cells is transiently upregulated following TCR and CD28 engagement, and this upregulation is IL-4-independent. Upregulation enhances functional chemotactic responses to I-309 and TARC. Flow cytometry, chemotaxis assay, cytokine neutralization Journal of immunology (Baltimore, Md. : 1950) Medium 9820476
1998 TARC (CCL17) and MIP-1β (CCL4) were identified as additional functional CCR8 ligands, inducing chemotaxis in CCR8-transfected Jurkat cells. Stable transfection of CCR8 into Jurkat cells, chemotaxis assay European journal of immunology Medium 9521068
1998 CCR8 serves as a co-receptor for HIV-1 infection; diverse T-cell tropic, dual-tropic, and macrophage-tropic HIV-1 strains can use CCR8, and I-309 (CCL1) potently inhibits HIV-1 envelope-mediated cell-cell fusion and virus infection through CCR8. Cell-cell fusion assay, virus infection assay, calcium flux, flow cytometry, pertussis toxin inhibition The Journal of biological chemistry High 9417093
1998 TER1/CCR8 is expressed in brain-derived CD4+ cells and T cells and functions as a co-receptor for brain-cell-tropic HIV-1 variants that are resistant to M-tropic and T-tropic strains. Degenerate PCR, expression of TER1 in CD4+ resistant cells, infection assay Biochemical and biophysical research communications Medium 9480837
1999 HHV-8-encoded vMIP-I selectively binds to and signals through CCR8 as an agonist (inducing Ca2+ flux in T cells), while vMIP-II and vMCC-I act as CCR8 antagonists. A comprehensive ligand binding fingerprint for CCR8 identified four high-affinity ligands (vMIP-I, vMIP-II, vMCC-I, and human I-309). Competitive radioligand binding with 65 chemokines, calcium mobilization assay in human T cells The Journal of biological chemistry High 10419462
1999 vMIP-I (KSHV-encoded) is a specific agonist for CCR8: it binds with high affinity, induces calcium flux, and drives chemotaxis in CCR8-transfected Y3 cells. vMIP-I does not interact with CCR5 or 11 other receptors tested. Calcium flux assay, chemotaxis assay, competition binding in CCR8-transfected cells The Journal of experimental medicine High 10377196
2000 The molluscum contagiosum poxvirus-encoded MC148 is a highly selective CCR8 antagonist that binds with high affinity only to CCR8 among 16 chemokine receptors and blocks I-309/CCR8-induced calcium mobilization and chemotaxis without affecting other chemokine receptors. Competitive binding with radiolabeled chemokines, calcium mobilization assay, chemotaxis assay across 16 receptors The Journal of experimental medicine High 10620615
2000 CCR8 is expressed on human thymocytes (both immature and mature) and functions as an HIV-1 co-receptor: I-309 inhibits fusion of thymocytes with HIV-1 X4 or X4R5 envelope-expressing cells and partially inhibits productive HIV-1 infection. 125I-I-309 binding on primary thymocytes, cell-cell fusion assay, productive infection assay Journal of virology High 10888633
2001 CCR8 is expressed on human vascular endothelial cells (HUVECs) and mediates endothelial cell chemotaxis in response to I-309 and vMIP-I. Pertussis toxin and anti-CCR8 antibody blocked this chemotaxis, confirming G protein-coupled, CCR8-dependent signaling in endothelial cells. Chemotaxis assay, antibody neutralization, pertussis toxin inhibition, RNA blot, immunohistochemistry Blood Medium 11133740
2001 CCR8 and CCR4 are specifically expressed on human CD4+CD25+ regulatory T cells (Tregs), which vigorously respond to CCR8 ligands CCL1 and CCL22. CCR4 ligands (CCL17, CCL22) secreted by mature dendritic cells preferentially attract Treg cells, and the migrated CCR8/CCR4-expressing population shows reduced alloproliferative response. Flow cytometry, chemotaxis assay with sorted CD4+CD25+ vs CD4+CD25- T cells, functional alloproliferation assay The Journal of experimental medicine High 11560999
2003 CCR8 mediates human vascular smooth muscle cell (VSMC) chemotaxis in response to CCL1 and vCCL1, and this is blocked by anti-CCR8 antibody and pertussis toxin. CCR8 activation by CCL1 also induces pro-MMP-2 mRNA and protein secretion, which contributes to VSMC migration, as shown by MMP-2 antibody inhibition. Chemotaxis assay, antibody/pertussis toxin inhibition, RT-PCR, MMP-2 ELISA/western blot, poxvirus MC148 blockade Blood Medium 14576057
2003 CCR8-dependent activation of the RAS/MAPK (ERK1/2) pathway mediates anti-apoptotic activity of CCL1 and vMIP-I in thymic lymphoma cells. This was demonstrated using pertussis toxin, the MEK inhibitor PD98059, a dominant negative M-RAS, and the CCR8 antagonist MC148. Apoptosis assay, pertussis toxin inhibition, ERK phosphorylation assay, MEK inhibitor (PD98059), dominant negative M-RAS, MC148 antagonist, CCR8-transfected CHO cells European journal of immunology High 12645948
2003 CCR8 mediates rescue of thymic lymphoma cells and murine thymocytes from dexamethasone-induced apoptosis via an ERK-dependent pathway. The CCR8 antagonist MC148 specifically blocks the anti-apoptotic activity of vMIP-I and CCL1. Apoptosis assay, ERK pathway analysis, MC148 antagonist blockade, CCR8-specific agonist vMIP-1 Journal of leukocyte biology Medium 12525579
2004 Post-translational modifications of murine CCR8 regulate its activity: tyrosine sulfation at positions Y14/Y15 is critical for CCL1 binding and calcium signaling (Y14F/Y15F double mutant essentially inactive), while N-linked glycosylation at N8 and O-linked modifications at T10/T12 have minor effects on ligand binding. Site-directed mutagenesis (Tyr→Phe, Asn→Gln, Thr/Ser→Ala), flow cytometry with CCL1-Fc fusion, calcium flux assay The Journal of biological chemistry High 14736884
2005 CCR8 is expressed on Langerhans-type dendritic cells (DCs), mast cells, and dermal endothelial cells. CCL1 recruits both T cells and Langerhans cell-like DCs, and synergizes with CXCL12 (SDF-1α) in promoting this recruitment. CCR8 is recruited from intracytoplasmic stores to the cell surface upon T cell activation. Immunofluorescence, flow cytometry, in vitro chemotaxis assay, in vitro DC differentiation, CCL1/CXCL12 synergy experiments Journal of immunology (Baltimore, Md. : 1950) Medium 15814739
2005 CCR8 expression defines IL-10-producing CD4+CD25+ T cells in Th2-type granulomatous inflammation. CCR8-deficient mice showed significantly impaired IL-10 production and reduced granuloma eosinophils in a Schistosoma egg-antigen model; adoptive transfer of CCR8+/+ CD4+ T cells corrected these defects. CCR8-/- mice, adoptive transfer, cytokine mRNA quantification, BAL cell analysis Journal of immunology (Baltimore, Md. : 1950) Medium 15699124
2006 CCR8 undergoes beta-arrestin 1/2-dependent internalization upon ligand binding (CCL1 and vMIP-I), independently of Gαi signaling. NH2-terminal extension of CCL1 by a serine residue (Ser-CCL1) generates a partial agonist, indicating the NH2 terminus plays a role in binding to an intrahelical site. Glu-286 in TM helix 7 is critical for receptor surface trafficking, and CCL7 selectively antagonizes viral (but not host) chemokine activity at CCR8. Calcium flux, chemotaxis, receptor internalization assay, beta-arrestin expression, site-directed mutagenesis, CCL7 antagonism experiments The Journal of biological chemistry High 17023422
2007 A non-peptide CCR8 agonist (LMD-009) interacts with CCR8 through a binding pocket involving GluVII:06 (Glu286) as a critical anchor point, shared with non-peptide antagonists targeting CCR1, CCR2, and CCR5. Ala substitution of Glu286 reduced agonist potency ~1000-fold; Ala substitution of PheVI:16 (Phe254) produced a 19-fold gain-of-function. 29 mutations across 25 residues mapped the binding pocket. Site-directed mutagenesis (29 mutations), calcium flux, chemotaxis, inositol phosphate accumulation, 125I-CCL1 competitive binding Molecular pharmacology High 17652183
2007 CCR8 is expressed on peritoneal macrophages (PMφ) and up-regulated by inflammatory stimuli. CCL1 produced by both PMφ and peritoneal mesothelial cells (PMCs) promotes CCR8 expression (autocrine loop), drives cell aggregation, and upregulates plasminogen activator inhibitor-1. CCR8-deficient mice and anti-CCL1-treated mice exhibit significantly reduced postoperative peritoneal adhesions. CCR8-/- mice, anti-CCL1 neutralizing antibody, in vitro cell aggregation assay, RT-PCR, flow cytometry Journal of immunology (Baltimore, Md. : 1950) Medium 17404314
2007 Mast cell-derived CCL1 signals through CCR8 on CD4+ T lymphocytes to orchestrate mucosal lung inflammation, airway hyperresponsiveness, and mucus hypersecretion. CCR8 deficiency or CCL1 neutralization reduced these responses to the same degree as mast cell deficiency; adenoviral CCL1 delivery to lungs of mast cell-deficient mice restored the inflammatory phenotype. CCR8-/- mice, mast cell-deficient mice, CCL1 neutralization, adenoviral CCL1 delivery, airway hyperresponsiveness measurements, BAL cytokine analysis Journal of immunology (Baltimore, Md. : 1950) High 17641040
2007 CCR8 expression in CD4+CD25+ Tregs recruited to the pancreas during adoptive transfer of diabetogenic T cell clones; the only chemokine detectable ex vivo was CCL1, suggesting CCL1/CCR8 interaction mediates macrophage recruitment and activation (IL-1β, TNF-α, NO production) in type 1 diabetes. Adoptive transfer model, flow cytometry, ex vivo chemokine protein detection, macrophage functional assays Journal of immunology (Baltimore, Md. : 1950) Low 17947648
2008 Using adoptive transfer of CCR4-deficient or CCR8-deficient antigen-specific Th2 cells, CCR4 (not CCR8) was found to be required for efficient entry of antigen-specific Th2 cells into the lung and airways in allergic pulmonary inflammation. CCR8-deficient Th2 cells showed normal or increased accumulation in the lung. Adoptive transfer of CCR4-/- or CCR8-/- antigen-specific Th2 cells, flow cytometry, cytokine measurement, eosinophil/mucus quantification The Journal of allergy and clinical immunology High 19062085
2011 Mouse CCL8 is a selective CCR8 agonist (not a CCR2 agonist, unlike all other MCP chemokines). CCL8 responsiveness defined a population of CCR8-expressing inflammatory Th2 cells enriched for IL-5. CCR8- and CCL8-deficient mice showed markedly reduced eosinophilic inflammation in chronic atopic dermatitis. Adoptive transfer established CCR8 as a key regulator of Th2 cell recruitment into allergen-inflamed skin. Ccr8-/- and Ccl8-/- mice, adoptive transfer, receptor binding assays, calcium flux, atopic dermatitis mouse model, eosinophil quantification Nature immunology High 21217759
2012 C-terminal clipping of CCL1 by carboxypeptidase M (CPM) augments CCR8-mediated intracellular calcium release and anti-apoptotic activity in BW5147 cells, while reducing CCL1 binding affinity to CCR8, revealing a proteolytic regulatory mechanism for the CCL1-CCR8 axis. In vitro CPM enzymatic cleavage, mass spectrometry, calcium mobilization assay, binding assay, apoptosis assay with CPM inhibitor control PloS one Medium 22479563
2013 CCR8 is a functional receptor for CCL18: CCL18 induces chemotaxis and calcium flux in CCR8-transfected cells, binds CCR8 with high affinity, induces CCR8 internalization, and competes with CCL1 for CCR8 binding. CCL1 and CCL18 cross-desensitize CCR8 on transfected cells and human Th2 cells. CCR8-deficient mouse Th2 cells fail to migrate to CCL18. CCR8 transfection, chemotaxis assay, calcium flux, competitive binding, receptor internalization, cross-desensitization, Ccr8-/- mouse Th2 cell migration The Journal of experimental medicine High 23999500
2014 CCR8 is required for LPS-triggered cytokine production (TNF-α, IL-6, IL-10) specifically in peritoneal macrophages but not bone marrow-derived macrophages. CCR8-dependent cytokine production involves cross-talk with TLR-4 signaling via JNK and NF-κB pathways. A CCR8 antagonist (R243) phenocopied CCR8 deficiency and attenuated peritoneal adhesions in vivo. CCR8-/- mice, TLR ligand stimulation, cytokine ELISA, JNK/NF-κB inhibitors, R243 CCR8 antagonist, in vivo adhesion model PloS one Medium 24714157
2017 CCL1 signaling through CCR8 on Tregs induces STAT3-dependent upregulation of FOXp3, CD39, IL-10, and granzyme B, enhancing Treg suppressive activity. CCL1 produced by Tregs at autoimmune sites creates a self-feeding autocrine loop that upregulates CCR8 on Tregs. CCR8-/- mice in adoptive transfer experiments confirmed the essential role of CCR8 in Treg-mediated suppression of EAE. Human PBMC activation assays, STAT3 inhibition, CCL1-Ig administration, CCR8-/- mouse adoptive transfer, EAE model, flow cytometry for CD39/granzyme B/IL-10 Proceedings of the National Academy of Sciences of the United States of America High 28533380
2018 CCR8 on CD301b+ dendritic cells (DCs) mediates their migration from the subcapsular sinus into the lymph node parenchyma following allergen exposure, synergizing with CCR7/CCL21 in a Src-kinase-dependent manner. CCL8 produced by CD169+SIGN-R1+ macrophages in interfollicular regions provides the CCR8 signal. In CCR8-deficient mice, CD301b+ DCs are trapped in the subcapsular sinus and cannot enter the parenchyma, resulting in defective Th2 differentiation. CCR8-/- mice, DC migration tracking by flow cytometry and imaging, CCL8 source identification, Src kinase inhibition, CCR7 expression analysis, Th2 differentiation assays Immunity High 30170811
2019 Activated ILC2s produce CCL1 and are a major CCL1 source in vivo; CCL1 signaling via CCR8 on ILC2s regulates their proliferation and capacity to protect against helminthic infections, establishing a CCR8-dependent autocrine/paracrine feed-forward loop for ILC2 self-renewal. In vitro CCR8 chemotaxis assay, in vivo CCR8-/- mouse models, CCL1 measurement by ELISA, helminth infection model, proliferation assays The Journal of experimental medicine Medium 31537642
2019 CCR8 expression on Tregs was upregulated by TCR-mediated signaling in an NF-κB-dependent fashion. CCR8 was not essential for the recruitment, activation, or suppressive capacity of tumor-infiltrating Tregs per se, but ADCC-prone anti-CCR8 nanobody-Fc fusion proteins depleted ti-Tregs in an NK cell-dependent manner and elicited antitumor immunity synergizing with anti-PD-1. scRNA-seq, flow cytometry, NF-κB inhibition, nanobody generation, ADCC assay, NK cell depletion in vivo, LLC-OVA and MC38 tumor models Journal for immunotherapy of cancer High 33589525
2019 Disruption of the CCL1-CCR8 axis (via CCL1 and Apoe double deficiency or anti-CCR8 blocking antibodies) promotes atherosclerosis by reducing Treg recruitment to the aorta, decreasing IL-10 levels, and shifting toward a Th1 response, establishing a protective role for CCL1-CCR8 in vascular inflammation. Ccl1/Apoe double-KO mice, flow chamber adhesion assay, intravital microscopy, anti-CCR8 blocking antibody, Treg quantification in aorta/spleen, cytokine measurement Journal of molecular and cellular cardiology Medium 31121182
2021 CCR8 expression on tumor-infiltrating Tregs is upregulated by TCR stimulation but is not essential for their recruitment, activation, or suppressive function. Depletion of CCR8+ tumor Tregs via ADCC-capable anti-CCR8 antibody elicits antitumor immunity, reduces tumor growth, and synergizes with anti-PD-1 therapy without affecting peripheral Tregs. Fc-optimized anti-CCR8 antibody, CCR8-/- mouse tumors (MC38, B16), flow cytometry, ex vivo depletion in primary human tumor samples Cancer research High 33757978
2021 In bladder cancer, CCR8 expression in intratumoral Tregs maintains stability and potentiates suppressive function by upregulating transcription factors FOXO1 and c-MAF. CCR8 blockade destabilizes intratumoral Tregs into a fragile phenotype and reactivates antitumor immunity, augmenting anti-PD-1 benefits. Flow cytometry, ex vivo CCR8 blockade experiments, transcription factor analysis (FOXO1, c-MAF), TCGA bioinformatics, retrospective clinical cohort, anti-PD-1 combination Cancer immunology, immunotherapy : CII Medium 32367308
2022 CCR8+ tumor Tregs are predominantly clonally expanded cells activated by tumor-associated antigens. Anti-CCR8 mAb treatment selectively eliminated these multiclonal tumor Tregs (sparing peripheral Tregs), expanded tumor-specific CD8+ T cells, and generated memory-type antitumor immunity without autoimmunity in mice. scRNA-seq, TCR clonotype analysis, CCR8-/- mice, anti-CCR8 mAb (depleting vs. non-depleting), flow cytometry, tumor rechallenge memory assays Proceedings of the National Academy of Sciences of the United States of America High 35140181
2022 Donor kidney-resident macrophages upregulate CCL8 upon transplantation, which promotes CCR8-expressing recipient T cell (CD4, CD8, γδ T cell) infiltration into kidney allografts. Blocking CCL8-CCR8 or depleting donor kidney resident macrophages significantly inhibited early allograft immune infiltration and improved allograft function. Murine allogeneic kidney transplant model, CCL8/CCR8 blockade, macrophage depletion, flow cytometry for immune infiltrates, allograft function assays Journal of the American Society of Nephrology : JASN Medium 35973731
2022 Intracellular lactate upregulates CCR8 expression in CD4+ T cells and macrophages through histone H3K18 lactylation at the CCR8 gene promoter, linking tumor glycolysis to CCR8-expressing immunosuppressive Tregs in glioblastoma. ChIP assay for H3K18 lactylation at CCR8 promoter, luciferase reporter assay, RT-qPCR, western blot, flow cytometry, LDHA inhibitor (oxamate) Journal of experimental & clinical cancer research : CR Medium 37770937
2022 Tumor-derived exosomes promote CCL1 secretion by lung fibroblasts, which activates CCR8 on T cells to drive Treg differentiation and establish an immunologically tolerant pre-metastatic niche. Inhibiting CCL1-CCR8 axis with AZ084 suppressed Treg differentiation and tumor metastasis in the lung. LLC-exo in vitro co-culture, CCL1 ELISA, CCR8 flow cytometry, AZ084 CCR8 antagonist, GW4869 exosome inhibitor, in vivo pre-metastatic niche mouse model Cancer immunology, immunotherapy : CII Medium 35428909
2024 TNF-α in the colorectal cancer microenvironment upregulates CCR8 expression in Tregs via TNFR2/NF-κB signaling and the FOXP3 transcription factor. PD-1 blockade induces additional CCR8+ Treg infiltration; TNFR2 depletion or blockade suppresses tumor progression by reducing CCR8+ Treg infiltration. NF-κB/TNFR2 inhibition, FOXP3 ChIP, Tnfr2-/- mouse tumor models, anti-PD-1 combination, flow cytometry Journal of molecular cell biology Medium 37935468
2021 Small molecule CCR8 agonists (ZK756326, AZ6, vCCL1) display biased signaling relative to human CCL1: while all induce full agonist calcium mobilization, Gβγ signaling is required for CCL1-induced but not small molecule agonist-induced cell migration. Small molecule agonists show higher efficacy for β-arrestin 1 recruitment, which occurs independently of Gαi signaling. Calcium mobilization, cellular impedance (xCELLigence), cell migration assay, β-arrestin 1/2 recruitment assay, Gβγ inhibitor (gallein), Gαi inhibitor (pertussis toxin) Biochemical pharmacology Medium 33872569
2025 CCR8+ Tregs are specifically enriched in human first-trimester decidua, produced in part through CCL1 secreted by decidual CD49a+ NK cells. Depletion of CCR8+ dTregs increased fetal loss susceptibility with altered decidual immune profiles; adoptive transfer of CCR8+ Tregs rescued fetal loss in abortion-prone mice, establishing a CCR8+ Treg subset as essential for maternal-fetal tolerance. scRNA-seq, TCR sequencing, CCR8+ dTreg depletion in mice, adoptive transfer rescue experiments, CCL1 ELISA, flow cytometry Science immunology High 40249828

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. The Journal of experimental medicine 707 11560999
1998 Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. Journal of immunology (Baltimore, Md. : 1950) 346 9820476
2001 The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. The Journal of clinical investigation 333 11390417
1998 The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. Journal of immunology (Baltimore, Md. : 1950) 329 9670926
2020 CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. International journal of molecular sciences 301 33076281
2011 Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nature immunology 257 21217759
2017 CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proceedings of the National Academy of Sciences of the United States of America 192 28533380
1997 Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. The Journal of experimental medicine 177 9207005
2005 CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. Journal of immunology (Baltimore, Md. : 1950) 169 15814739
2021 Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. Journal for immunotherapy of cancer 164 33589525
2013 Identification of human CCR8 as a CCL18 receptor. The Journal of experimental medicine 157 23999500
2022 CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings of the National Academy of Sciences of the United States of America 151 35140181
1999 HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. The Journal of biological chemistry 148 10419462
1997 Identification of CCR8, the receptor for the human CC chemokine I-309. The Journal of biological chemistry 147 9211859
1998 The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. The Journal of biological chemistry 142 9417093
2023 Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. Journal of experimental & clinical cancer research : CR 124 37770937
1999 The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. The Journal of experimental medicine 117 10377196
2006 CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 115 17082609
2000 A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. The Journal of experimental medicine 108 10620615
2018 Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer. Cancer research 105 30026324
2008 Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. The Journal of allergy and clinical immunology 105 19062085
2007 TER1, the RNA subunit of fission yeast telomerase. Nature structural & molecular biology 99 18157152
2018 The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response. Immunity 98 30170811
2021 Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. Cancer research 97 33757978
2007 Identification and characterization of the Schizosaccharomyces pombe TER1 telomerase RNA. Nature structural & molecular biology 94 18157149
1998 Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. European journal of immunology 91 9521068
2003 CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. Journal of immunology (Baltimore, Md. : 1950) 83 12496446
2018 Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of extracellular vesicles 79 29696074
2003 Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. Journal of immunology (Baltimore, Md. : 1950) 77 12574386
2018 CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin. Journal of immunology (Baltimore, Md. : 1950) 75 29427415
1998 Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. Biochemical and biophysical research communications 75 9480837
2022 Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer immunology, immunotherapy : CII 74 35428909
2021 CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. Immunology 73 33838058
2001 The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood 72 11133740
1998 Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3. Journal of immunology (Baltimore, Md. : 1950) 65 9469461
2007 Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. Journal of immunology (Baltimore, Md. : 1950) 63 17947648
2003 Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 61 14576057
2019 A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation. The Journal of experimental medicine 58 31537642
2005 CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. Journal of immunology (Baltimore, Md. : 1950) 58 15699124
2007 Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions. Journal of immunology (Baltimore, Md. : 1950) 56 17404314
2007 Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1:CCR8 axis. Journal of immunology (Baltimore, Md. : 1950) 56 17641040
2013 Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research 55 23363815
1996 Molecular cloning of TER1, a chemokine receptor-like gene expressed by lymphoid tissues. Journal of immunology (Baltimore, Md. : 1950) 53 8816377
2003 CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. European journal of immunology 48 12645948
2007 Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Molecular pharmacology 47 17652183
2018 CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells. Molecular medicine reports 46 30592282
2005 Sap1p binds to Ter1 at the ribosomal DNA of Schizosaccharomyces pombe and causes polar replication fork arrest. The Journal of biological chemistry 46 16195226
2002 Increased responsiveness of murine eosinophils to MIP-1beta (CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8. Journal of leukocyte biology 46 12050188
2020 CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. Cancer immunology, immunotherapy : CII 45 32367308
2013 Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. Journal of hepatology 45 23811304
2000 CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. Journal of virology 44 10888633
2000 LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8. Blood 41 10910894
2007 CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. Journal of neurochemistry 39 17181556
2022 The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. Scientific reports 38 35354899
2019 Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. Journal of molecular and cellular cardiology 38 31121182
2003 The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway. Journal of leukocyte biology 38 12525579
2022 Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology 36 36352891
2017 Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target - Evidence from a mouse diabetic neuropathy model. International immunopharmacology 36 28961489
2004 Analysis of post-translational CCR8 modifications and their influence on receptor activity. The Journal of biological chemistry 36 14736884
2014 Chemokine receptor CCR8 is required for lipopolysaccharide-triggered cytokine production in mouse peritoneal macrophages. PloS one 35 24714157
2012 Schizosaccharomyces pombe Ccq1 and TER1 bind the 14-3-3-like domain of Est1, which promotes and stabilizes telomerase-telomere association. Genes & development 35 22215813
2021 Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Vitamin D Signaling Pathway. Frontiers in immunology 34 34025655
2010 Expression of CCR8 is increased in asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 34 20455898
2010 Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 33 20947116
2006 Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8). Journal of medicinal chemistry 33 16640325
2006 Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist. The Journal of biological chemistry 31 17023422
2024 Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells. Journal of molecular cell biology 29 37935468
2022 Chemokine Receptor-Targeted Therapies: Special Case for CCR8. Cancers 29 35158783
2022 Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model. Cell reports 29 35417708
2005 Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Molecular pharmacology 28 16221874
2024 Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer. Journal of translational medicine 21 39080766
2023 S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. Molecular cancer therapeutics 21 37420296
2022 Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. Journal of the American Society of Nephrology : JASN 21 35973731
2003 Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus. The Journal of biological chemistry 21 12551893
2025 CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends in immunology 20 39890548
2023 Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. Journal of medicinal chemistry 20 36988587
2011 Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochemical pharmacology 20 22209712
2007 Combination of 17beta-estradiol with the environmental pollutant TCDD is involved in pathogenesis of endometriosis via up-regulating the chemokine I-309-CCR8. Fertility and sterility 20 17693327
2004 Genetic dissection of the Kluyveromyces lactis telomere and evidence for telomere capping defects in TER1 mutants with long telomeres. Eukaryotic cell 20 15075267
2021 Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway. The American journal of pathology 19 33460563
2012 C-terminal clipping of chemokine CCL1/I-309 enhances CCR8-mediated intracellular calcium release and anti-apoptotic activity. PloS one 19 22479563
2007 Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE. Scandinavian journal of immunology 18 17850582
2023 Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile. Journal of immunology (Baltimore, Md. : 1950) 17 37350632
2011 CCR8 signaling influences Toll-like receptor 4 responses in human macrophages in inflammatory diseases. Clinical and vaccine immunology : CVI 17 21976223
2025 CCR8+ decidual regulatory T cells maintain maternal-fetal immune tolerance during early pregnancy. Science immunology 16 40249828
2022 C8Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry. Monoclonal antibodies in immunodiagnosis and immunotherapy 16 35377236
2022 Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow Cytometry and Immunocytochemistry. Monoclonal antibodies in immunodiagnosis and immunotherapy 16 35483056
2019 Spinal CCL1/CCR8 regulates phosphorylation of GluA1-containing AMPA receptor in postoperative pain after tibial fracture and orthopedic surgery in mice. Neuroscience research 16 31121204
2019 CCR8 leads to eosinophil migration and regulates neutrophil migration in murine allergic enteritis. Scientific reports 16 31270368
2014 CCR8 regulates contact hypersensitivity by restricting cutaneous dendritic cell migration to the draining lymph nodes. International immunology 16 25344933
2001 MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human but not murine CCR8. Journal of leukocyte biology 16 11493620
2025 Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 15 40056978
2012 Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions. British journal of pharmacology 15 22708643
2007 Remission of chronic fungal asthma in the absence of CCR8. The Journal of allergy and clinical immunology 15 17321573
2023 CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation. Journal of translational medicine 14 37950246
2021 Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists. Biochemical pharmacology 14 33872569
2017 Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochemistry international 14 29248693
2015 In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study. Journal of biomolecular structure & dynamics 14 25617117
2024 Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clinical and experimental medicine 13 38856863
2022 TGF-β-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells. Experimental lung research 13 35377281